ANGPTL3 and familial hyperaldosteronism: Our data highlights the existence of alternative pathways for hepatic LDL uptake independently of the LDLR and provides an additional mechanism that could explain the reduction of plasma LDL observed in FH patients treated with ANGPTL3 inhibitors.